Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis

OPERA I and OPERA II Clinical Investigators

Research output: Contribution to journalArticlepeer-review


BACKGROUND B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a humanized monoclonal antibody that selectively depletes CD20+ B cells. METHODS In two identical phase 3 trials, we randomly assigned 821 and 835 patients with relapsing multiple sclerosis to receive intravenous ocrelizumab at a dose of 600 mg every 24 weeks or subcutaneous interferon beta-1a at a dose of 44 μg three times weekly for 96 weeks. The primary end point was the annualized relapse rate. RESULTS The annualized relapse rate was lower with ocrelizumab than with interferon beta-1a in trial 1 (0.16 vs. 0.29; 46% lower rate with ocrelizumab; P
Original languageEnglish
Pages (from-to)221-234
Number of pages14
JournalNew England Journal of Medicine
Issue number3
Publication statusPublished - 2017


Dive into the research topics of 'Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis'. Together they form a unique fingerprint.

Cite this